Because novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus) have therapeutic potential through activation of autophagy in the context of various diseases including cancers (Yazbeck et al., 2008; Gibbons et al., 2009; Cerni et al., 2019; Zou et al., 2020), it is likely that these mTOR inhibitors have beneficial effects for antibacterial autophagy and host defense against Mtb infection. The gene discussed is MTOR; the disease is cancer.